A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- Sponsors Valneva
- 07 Jan 2019 According to a Valneva media release, phase 1 revaccination data post month six and unblinded safety and immunogenicity data at dose group level is expected by mid-year 2019.
- 07 Jan 2019 Interim results including blinded, pooled safety and immunogenicity data up to Day 28 were presented in a Valneva media release.
- 21 Dec 2018 According to a Valneva media release, the company will release initial data from he study in coming weeks.